Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.55 |
| ▸ | CA3 | P07451 | 3/20 | 0.55 |
| ▸ | CA4 | P22748 | 3/20 | 0.55 |
| ▸ | CA6 | P23280 | 3/20 | 0.55 |
| ▸ | CA5A | P35218 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11855965 | 0.89 | CA2 (0.67) | CA2CA1CA12CA9CA14 | |
| SCHEMBL11419996 | 0.89 | CA2 (0.67) | CA2CA1CA12CA9CA14 | |
| SCHEMBL3158508 | 0.89 | CA2 (0.67) | CA2CA1CA12CA9CA14 | |
| SCHEMBL85535 | 0.87 | MEN1 (0.64) | CA2CA1CA12CA9CA14 | |
| SCHEMBL27713254 | 0.85 | MEN1 (0.55) | CA2CA1CA12CA9CA14 | |
| SCHEMBL19025562 | 0.84 | MEN1 (0.62) | CA2CA1CA12CA9CA14 | |
| Fluoride SCHEMBL27503363 | 0.84 | MEN1 (0.62) | CA2CA1CA12CA9CA14 | |
| SCHEMBL8311585 | 0.84 | MEN1 (0.54) | CA2CA1CA12CA9CA14 | |
| SCHEMBL11854911 | 0.83 | CA1 (0.70) | CA2CA1CA12CA9CA14 | |
| SCHEMBL10451887 | 0.83 | CA1 (0.70) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3649110-B1 | MYCOBACTERIUM-TUBERCOLOSIS-THIOREDOXIN REDUCTASE INHIBITOR AS ANTITUBERCULOSIS DRUG | UNIV DORTMUND TECH (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-11078185-B2 | Mycobacterium tuberculosis—thioredoxin reductase inhibitor as an antitubercular agent | TECHNISCHE UNIVERSITAT DORTMUND (DE) | 2021-08-03 | — | — | US | disclosed |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2020-09-10 | — | — | US | disclosed |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2020-09-10 | — | — | US | disclosed |
| EP-3649110-A1 | MYOBACTERIUM TUBERCULOSIS-THIOREDOXIN REDUCTASE INHIBITOR AS AN ANTITUBERCULAR AGENT | Technische Universität Dortmund (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200123130-A1 | Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent | TECHNISCHE UNIVERSITAT DORTMUND (DE) | 2020-04-23 | — | — | US | disclosed |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-09-05 | — | — | US | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| EP-2611777-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL]AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-0102476-B1 | METHOD OF MODULATING THE IMMUNE RESPONSE SYSTEM IN MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1986-11-05 | — | — | EP | disclosed |
| US-4554381-A | BORON TRIFLUORIDE, HYDROFLUORIC ACID | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-11-19 | — | — | US | disclosed |
| US-4532349-A | 2-Amino-4'(phenylsulfonyl) acetanilides | AMERICAN CYANAMID COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
| EP-0102476-A1 | Method of modulating the immune response system in mammals | AMERICAN CYANAMID COMPANY (US) | 1984-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | CA2 1644/4885CA1 2588/4885CA12 2172/4885 |
| US-20200123130-A1 | Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent | TXNRD1, TXNRD3, TXNRD2 | CA2 4076/4885CA1 4845/4885CA12 4858/4885 |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | CA2 1515/4885CA1 2843/4885CA12 2541/4885 |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | CA2 1644/4885CA1 2588/4885CA12 2172/4885 |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | CA2 1515/4885CA1 2843/4885CA12 2541/4885 |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CA2 1384/4885CA1 2998/4885CA12 2746/4885 |
| US-11078185-B2 | Mycobacterium tuberculosis—thioredoxin reductase inhibitor as an antitubercular agent | TXNRD3, TXNRD1, TXN | CA2 4685/4885CA1 4867/4885CA12 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.